| 12049465 |
Tricyclic compounds and their use as phosphodiesterase inhibitors |
Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola +2 more |
2024-07-30 |
$542,147,000 |
| 11472805 |
Tricyclic compounds and their use as phosphodiesterase inhibitors |
Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola +2 more |
2022-10-18 |
$393,425,000 |
| 11390623 |
6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands |
Thomas Allen Chappie, Jaclyn Louise Henderson, Joseph Michael Young, Bethany Lyn Kormos, Nandini Chaturbhai Patel +4 more |
2022-07-19 |
$2,227,040,000 |
| 11312713 |
Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors |
Michael Aaron Brodney, Thomas Allen Chappie, Jinshan Chen, Jotham Wadsworth Coe, Karen Coffman +14 more |
2022-04-26 |
$777,515,000 |
| 11161844 |
Cyclic substituted imidazo[4,5-c]quinoline derivatives |
Thomas Allen Chappie, Paul Galatsis, Michelle Renee Garnsey, Christopher John Helal, Jaclyn Louise Henderson +5 more |
2021-11-02 |
$709,757,000 |
| 10738063 |
6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola +2 more |
2020-08-11 |
$655,725,000 |
| 10590128 |
6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands |
Thomas Allen Chappie, Jaclyn Louise Henderson, Joseph Michael Young, Bethany Lyn Kormos, Nandini Chaturbhai Patel +4 more |
2020-03-17 |
$194,251,000 |
| 10323042 |
6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola +2 more |
2019-06-18 |
$923,940,000 |
| 10131669 |
Pyrazolopyrimidine compounds |
Thomas Allen Chappie, Patrick Robert Verhoest, Nandini Chaturbhai Patel, Matthew Merrill Hayward, Christopher John Helal +3 more |
2018-11-20 |
$851,493,000 |
| 10039753 |
Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors |
Karen Coffman, Paul Galatsis, Michelle Renee Garnsey, Jaclyn Louise Henderson, Bethany Lyn Kormos +5 more |
2018-08-07 |
$243,216,000 |
| 9695171 |
3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors |
Paul Galatsis, Matthew Merrill Hayward, Bethany Lyn Kormos, Lei Zhang, Jaclyn Louise Henderson +3 more |
2017-07-04 |
|
| 9642855 |
Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors |
Paul Galatsis, Matthew Merrill Hayward, Bethany Lyn Kormos, Lei Zhang, Antonia Friederike Stepan +3 more |
2017-05-09 |
$329,222,000 |
| 9156845 |
4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors |
Paul Galatsis, Matthew Merrill Hayward, Bethany Lyn Kormos, Lei Zhang, Antonia Friederike Stepan +3 more |
2015-10-13 |
$674,982,000 |
| 8536164 |
Fused pyridine compounds as casein kinase inhibitors |
Todd W. Butler, Ramalakshmi Yegna Chandrasekaran, Scot Richard Mente, Chakrapani Subramanyam |
2013-09-17 |
$306,164,000 |
| 8518944 |
Compounds as casein kinase inhibitors |
Chakrapani Subramanyam |
2013-08-27 |
$352,800,000 |
| 8389743 |
Histamine-3 receptor antagonists |
Ramalakshmi Yegna Chandrasekaran, Todd W. Butler |
2013-03-05 |
$213,487,000 |
| 8314139 |
Toluene sulfonic acid salt of a therapeutic compound and pharmaceutical compositions thereof |
Todd W. Butler |
2012-11-20 |
$605,825,000 |
| 8178574 |
Tosylate salt of trans-N-isobutyl-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-yl-methyl)-phenyl] cyclobut anecarboxamide |
Todd W. Butler |
2012-05-15 |
$216,942,000 |
| 8158673 |
Histamine-3 receptor antagonists |
Ramalakshmi Yegna Chandrasekaran, Todd W. Butler |
2012-04-17 |
$210,372,000 |
| 7812040 |
Histamine-3 receptor antagonists |
— |
2010-10-12 |
$603,448,000 |
| 7300944 |
Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 inhibitors |
Daniel Wei-Shung Kung |
2007-11-27 |
$106,842,000 |
| 7300943 |
GSK-3 inhibitors |
— |
2007-11-27 |
$106,842,000 |
| 7241798 |
NK1 antagonists |
Barbara E. Segelstein, Willard M. Welch, Jr. |
2007-07-10 |
$150,041,000 |
| 7115600 |
Histamine-3 receptor modulators |
Ramalakshmi Yegna Chandrasekaran |
2006-10-03 |
$964,167,000 |
